tirzepatide dosing for weight loss georgia Injections & Clinics Near You Microdosing Tirzepatide Chart: A Weekly

SURMOUNT-5 and aggregate data from previous trials reveal a notable pattern: Tirzepatide causes less gastrointestinal distress than Semaglutide despite producing greater weight loss

Clinical trial results vs real-world programmes In clinical trials, participants taking semaglutide achieved around 15-17% weight loss at 68 weeks

As Healio previously reported, once-weekly semaglutide conferred a 14.9% weight reduction at 68 weeks for adults with obesity in the STEP 1 trial, and tirzepatide was tied to up to 20.9% weight loss at 72 weeks in the SURMOUNT-1 trial

Very common side effects for both include nausea, diarrhoea, vomiting, and constipation